Catalyst Pharmaceuticals Inc.

At $31.49, Catalyst Pharmaceuticals' price is 35% below the $48.38 a share fair value that Intrinsiqq's calculator gets from its earnings. It trades at 18.20 times earnings and 18.52 times free cash flow. The growth behind that figure is yours to set on the Intrinsic Value tab. See how to tell if a stock is overvalued.

Intrinsiqq's calculator puts Catalyst Pharmaceuticals' fair value at $48.38 a share. It grows earnings per share 20% a year for 5 years, applies an exit P/E of 18.1, and works back at a 10% yearly return. A 25% margin of safety gives a buy-below price of $36.29. Every input can be changed on the Intrinsic Value tab.

Catalyst Pharmaceuticals scores 73 out of 100 on Intrinsiqq's quality score, which makes it a solid business on these measures. The score blends 8 checks computed from SEC filings. Its best check is revenue growth at 29.2%, and its weakest is share count change at 13.9%. The Quality tab shows every check against its target.

No. Catalyst Pharmaceuticals (CPRX) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Over the last twelve months it returned cash through share buybacks instead, equal to a 0.7% buyback yield. The Dividends tab shows its cash returns.